FXCM Releases New Features on the Trading Station Platform
Aug 29, 2016 12:30 pm UTC| Business
NEW YORK, Aug. 29, 2016 -- FXCM Inc. (NYSE:FXCM), a leading online provider of forex trading, Contract for Difference (CFD), and related services, announces today the release of new features and trading tools for the...
Aug 29, 2016 12:30 pm UTC| Business
DELRAY BEACH, Fla., Aug. 29, 2016 -- PositiveID Corporation ("PositiveID") (OTCQB:PSID), a life sciences company focused on detection and diagnostics, today announced that it, in conjunction with its partner, ENSCO,...
Core-Mark Announces the Expiration of a Supply Agreement with Circle K Stores Inc.
Aug 29, 2016 12:30 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2016 -- Core-Mark Holding Company, Inc. (NASDAQ:CORE), one of the largest marketers of fresh and broad-line supply solutions to the convenience retail industry in North America,...
TRACY GLOVER GLASS LIGHTING DESIGNER LAUNCHES NEW DESIGNS FOR 2016
Aug 29, 2016 12:20 pm UTC| Business
BROOKLYN, N.Y., Aug. 29, 2016 -- Tracy Glover, the Rhode Island-based, hand-blown glass designer introduces new designs to her popular collection. As head of Tracy Glover Studio, she designs each piece and works with her...
Aug 29, 2016 12:18 pm UTC| Business
Albany, NY, Aug. 29, 2016 -- According to new study by Transparency Market Research (TMR) on the global digital therapeutics market, the increasing application of digital therapeutics in pharmaceuticals and biologics...
RedHill Biopharma Announces Approval of a European Patent Supporting RHB-104 for Multiple Sclerosis
Aug 29, 2016 12:01 pm UTC| Business
RedHill has received from the European Patent Office a Notice of Intention to Grant a new patent covering RHB-104 for multiple sclerosis (MS), expected to be valid until 2032, once grantedA Phase IIa proof-of-concept study...
RedHill Biopharma Announces Approval of a European Patent Supporting RHB-104 for Multiple Sclerosis
Aug 29, 2016 12:01 pm UTC| Business
RedHill has received from the European Patent Office a Notice of Intention to Grant a new patent covering RHB-104 for multiple sclerosis (MS), expected to be valid until 2032, once grantedA Phase IIa proof-of-concept study...